drugset
drugset / Trial / NCT05671029

Thorough QT/QTc of Pritelivir in Healthy Subjects

NCT05671029 ↗

Phase 1 Completed 64 enrolled AiCuris Anti-infective Cures AG
RandomizedParallel-groupDouble-blindPrevention

Summary

This Phase 1 clinical trial was a double-blind, single-center, randomized and placebo-controlled trial in which healthy male and female subjects received in 2 parallel-groups daily oral doses of pritelivir (Group 1) or matching placebo (Group 2). Within Group 2, a single oral administration of moxifloxacin (positive control) and corresponding matching placebo was administered in a 2-sequence crossover design (nested crossover).

Timeline

Start
2022-12-04
Primary completion
2023-05-18
Completion
2023-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg Oral
Subject Pritelivir Small molecule 400 mg Oral

Indications

No indication recorded.